Dupixent vs Trelegy Ellipta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 87% less per claim than Dupixent ($380.00 vs $2819.00). Neither drug has a generic alternative available. Total Medicare spending: Dupixent at $4.4B vs Trelegy Ellipta at $2.9B.
| Metric | Dupixent | Trelegy Ellipta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $2,819 | $380* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.4B | $2.9B |
| Total Claims | 1,560,000 | 7,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 35.2% | 19.8%* |
| Generic Available | No | No |
| Condition | Autoimmune Diseases | Asthma/COPD |
| Total Beneficiaries | 245,000 | 865,000 |
Trelegy Ellipta costs 87% less per claim than Dupixent ($380.00 vs $2819.00). Neither drug has a generic alternative available. Total Medicare spending: Dupixent at $4.4B vs Trelegy Ellipta at $2.9B.
Explore More
Comparing Dupixent and Trelegy Ellipta on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.